Title |
Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials
|
---|---|
Published in |
Arthritis Research & Therapy, April 2015
|
DOI | 10.1186/s13075-015-0621-6 |
Pubmed ID | |
Authors |
Kristin M Corapi, Mary Anne Dooley, William F Pendergraft |
Abstract |
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with diverse manifestations. Although the approval of new therapies includes only one agent in 50 years, a number of promising new drugs are in development. Lupus nephritis is a dreaded complication of SLE as it is associated with significant morbidity and mortality. Advancing the treatment of lupus nephritis requires well-designed clinical trials and this can be challenging in SLE. The major obstacles involve identifying the correct population of patients to enroll and ensuring that a clinically appropriate and patient-centered endpoint is being measured. In this review, we will first discuss the clinical utility of endpoints chosen to represent lupus nephritis in global disease activity scales. Second, we will review completed and active trials focused on lupus nephritis and discuss the endpoints chosen. There are many important lessons to be learned from existing assessment tools and clinical trials. Reviewing these points will help ensure that future efforts will yield meaningful disease activity measures and well-designed clinical trials to advance our understanding of lupus management. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 20% |
Spain | 2 | 20% |
United Kingdom | 1 | 10% |
Germany | 1 | 10% |
Unknown | 4 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 90% |
Scientists | 1 | 10% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 1% |
United States | 1 | 1% |
Unknown | 96 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 14 | 14% |
Student > Postgraduate | 13 | 13% |
Other | 12 | 12% |
Student > Bachelor | 11 | 11% |
Researcher | 10 | 10% |
Other | 25 | 26% |
Unknown | 13 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 65 | 66% |
Immunology and Microbiology | 5 | 5% |
Agricultural and Biological Sciences | 4 | 4% |
Biochemistry, Genetics and Molecular Biology | 3 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
Other | 2 | 2% |
Unknown | 17 | 17% |